Photodynamic therapy as a new treatment of cutaneous leishmaniasis

Eastern Mediterranean Health Journal

Volumn 12, Issue 6, 2006, Pages 902-908

  Ghaffarifar, F ^a   Jorjani, O ^a   Mirshams, M ^b   Miranbaygi, M H ^a   Hosseini, Z K ^b  

^a TARBIAT MODARES UNIVERSITY   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOLEVULINIC ACID; WATER OIL CREAM;

ADULT; AMASTIGOTE; ARTICLE; CLINICAL ARTICLE; CULTURE MEDIUM; DISEASE DURATION; ESTHETICS; FEMALE; HEALING; HUMAN; IRRADIATION; MALE; PHOTODYNAMIC THERAPY; SCAR FORMATION; SKIN INFLAMMATION; SKIN LEISHMANIASIS; SMEAR; TREATMENT DURATION; TREATMENT OUTCOME;

AMINOLEVULINIC ACID; DRUG ADMINISTRATION SCHEDULE; DRUG MONITORING; HUMANS; HYPERPIGMENTATION; INFLAMMATION; IRAN; LEISHMANIASIS, CUTANEOUS; PARASITOLOGY; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; RECURRENCE; TREATMENT OUTCOME; WOUND HEALING;

EID: 33847652118     PISSN: 10203397     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Hepburn NC. Cutaneous leishmaniasis. Clinical and experimental dermatology, 2000, 25:363-70.
2. Grevelink SA. Lerner EA. Leishmaniasis. Journal of the American Academy of Dermatology, 1996, 34:257-72.
3. Bermarn JD. Human leishmaniasis: clinical, diagnostic and chemotherapeutic developments in the last 10 years. Clinical infectious diseases, 1997, 24:684-703.
4. Gallis, HA. Amphotericin B: A commentary on its role as an antifungal agent and as a comparative agent in clinical trials. Clinical infectious diseases, 1996, 22(suppl. 2):S145-7.
5. Nguyen MT et al. Orally administered amphotericin B in the treatment of oral candidiasis in HIV-infected patients caused by azole-resistant Candida albicans. AIDS, 1996, 10(14):1745-7.
6. Graybill JR. Lipid formulations for amphotericin B: does the emperor need new clothes? Annals of internal medicine, 1996, 124(10):921-3.
7. Soto JL et al. Comparison of generic to branded pentavalent antimony for treatment of new world cutaneous leishmaniasis. American journal of tropical medicine and hygiene, 2004, 71:577-81.
8. Moskowitz PF, Kurban AK. Treatment of cutaneous leishmaniasis: retrospectives and advances for the 21st century. Clinical dermatology, 1999, 17:305-15.
9. Davidson RN. Practical guide for the treatment of leishmaniasis. Drugs, 1998, 56:1009-18.
10. Dolmans DEJGJ, Fukumura D, Jain RK. Photodynamic therapy for cancer. Nature reviews. Cancer, 2003, 3(5):380-7.
11. Wilson BC. Photodynamic therapy for cancer: Principles. Canadian journal of gastroenterology, 2002, 16(6):393-6.
12. Vrouenraets MB et al. Basic principles, applications in oncology and improved selectivity of photodynamic therapy. Anticancer research, 2003, 23:505-22.
13. Dougherty TJ et al. Photodynamic therapy. Journal of the National Cancer Institute, 1998, 90(12):889-905.
14. Dickson EFG, Goyan RL, Pottier RH. New directions in photodynamic therapy. Cellular and molecular biology, 2003, 48(8):939-54.
15. Roberts DJH, Cairnduff F. Photodynamic therapy of primary skin cancer: A review. British journal of plastic surgery, 1995, 48:360-70.
16. Peng Q et al. 5-aminolaevulinic acid-based photodynamic therapy. Cancer, 1997, 79:2282-308.
17. Allison RR, Mang TS, Dale BD. Photodynamic therapy for the treatment of nonmelanomatous cutaneous malignancies. Seminars in cutaneous medicine and surgery, 1998, 17(2):153-63.
18. Colussi VC, Feyes DK, Mukhtar H. Perspectives of photodynamic therapy for skin diseases. Skin pharmacology and applied skin physiology, 1998, 11:336-46.
19. Ruiz-Rodriguez R, Sanz-Sanchez T, Cordoba S. Photodynamic photorejuvenation. Dermatological surgery, 2002, 28:742-4.
20. Goldberg DJ, Cutler KB. Nonablative treatment of rhytids with intense pulsed light. Lasers in surgery and medicine, 2000, 26:196-200.
21. Bitter P Jr. Non-invasive rejuvenation of photo-damaged skin using serial, full-face intense pulsed light treatments. Dermatologic surgery, 2000, 26:835-43.
22. Gardlo K et al. Treatment of cutaneous leishmaniasis by photodynamic therapy. Journal of the American Academy of Dermatology, 2003, 48(6):893-6.
23. Enk CD et al. Treatment of cutaneous leishmaniasis with photodynamic therapy. Archives of dermatology, 2003, 139(4):432-4.
24. Hewaldt BL. Leishmaniasis. Lancet, 1999, 354:1191-9.
25. Chang KP, Chang CS, Sassa S. Heme biosynthesis in bacterium-protozoon symbioses: enzymic defects in host hemoflagellates and complemental role of their intracellular symbiotes. Proceedings of the National Academy of Sciences of the United States of America, 1975, 72:2979-83.
26. Sah JF et al. Genetic rescue of leishmania deficiency in porphyrin biosynthesis creates mutants: Suitable for analysis of cellular events in uroporphyria and for photodynamic therapy. Biological chemistry, 2002, 277(17):14902-9.
27. Abok K, Fredriksson BA, Brunk U. An experimental model system for leishmaniasis: effects of porphyrin compounds and menadione on Leishmania parasites engulfed by cultured macrophages. APMIS: acta pathologica, microbiologica, et immunologica Scandinavica, 1988, 96:543-51.
28. Stojiljkvic I, Evavold BD, Kumar V. Antimicrobial properties of porphyrins. Expert opinion on investigational drugs, 2001, 10:309-20.